AVR logo

ANTERIS TECHNOLOGIES GLOBAL

AVRNASDAQ
πŸ† #2743 by market capEarnings Nov 10US Equity
$6.09β–² $0.10 (+1.67%)
Pre-market Β· at close
πŸ””
Track AVR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$594M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-29.2%
Declining
πŸ“ŠGross Margin
37.0%
Healthy
πŸ’΅FCF Margin
-3927.8%
Thin
βš–οΈP/S Ratio
265.2x
Expensive
Otter Score
48
Weak
No chart data available for AVR.

Trading Snapshot

Day Range
$5.95 – $6.18
52-Week Range
$3.30 – $11.06
Volume (shares)
122,708
Avg Volume (shares)
β€”
Shares Outstanding
97.5M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$1M
P/E Ratio
-2.2
P/S Ratio
265.2x
EPS (TTM)
$-1.06
Dividend Yield
0.00%
Dilution (1yr)
+0.0%
AVR logo

ANTERIS TECHNOLOGIES GLOBAL

AVR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2Mβ–Ό βˆ’29.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-16.6%β–Ό βˆ’135.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$94Mβ–² +19.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$80Mβ–² +25.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.6Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10Mβ–Ό βˆ’$59M YoY
StockOtter Β· stockotter.space

About ANTERIS TECHNOLOGIES GLOBAL

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100
Analyst data unavailable.

Latest News & Updates

News unavailable.